Somatic mosaicism, the occurrence of multiple genetically distinct cell clones within the
same tissue, is an evitable consequence of human aging. The hematopoietic system is no …

Our understanding of the genetics of acute myeloid leukemia (AML) development from
myelodysplastic syndrome (MDS) has advanced significantly as a result of next-generation …

Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia
(AML) that is used for prognostic, predictive, monitoring, and efficacy-response …

PURPOSE Patients with acute myeloid leukemia (AML) in remission remain at risk for
relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable …

Abstract Next-generation sequencing (NGS)-based measurable residual disease (MRD)
monitoring in patients with acute myeloid leukemia (AML) is widely applicable and …

We accrued 201 patients of adult AML treated with conventional therapy, in morphological
remission, and evaluated MRD using sensitive error-corrected next generation sequencing …

Quantification of measurable residual disease (MRD) provides critical prognostic information
in acute myeloid leukemia (AML). A variety of platforms exist for MRD detection, varying in …

Allogeneic stem-cell transplant allows for the delivery of curative graft-versus-leukemia
(GVL) in patients with acute myeloid leukemia/myelodysplasia (AML/MDS). Surveillance of T …

Optimization of post‐remission therapies to maintain complete remission and prevent
relapse is a major challenge in treating patients with acute myeloid leukemia (AML) …

Abstract TP53 mutations (TP53 MTs) have been associated with poor outcomes in various
hematologic malignancies, but no data exist regarding its role in patients with myelofibrosis …